WBH Advisory Inc. Sells 1,290 Shares of Johnson & Johnson (NYSE:JNJ)

WBH Advisory Inc. lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 5.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,455 shares of the company’s stock after selling 1,290 shares during the quarter. WBH Advisory Inc.’s holdings in Johnson & Johnson were worth $3,537,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the business. Rogco LP increased its position in Johnson & Johnson by 1.2% during the 4th quarter. Rogco LP now owns 10,792 shares of the company’s stock valued at $1,561,000 after purchasing an additional 131 shares during the period. Hassell Wealth Management LLC acquired a new stake in Johnson & Johnson during the 4th quarter valued at approximately $321,000. Pathway Financial Advisors LLC increased its position in Johnson & Johnson by 1.5% during the 4th quarter. Pathway Financial Advisors LLC now owns 5,049 shares of the company’s stock valued at $730,000 after purchasing an additional 74 shares during the period. Monument Capital Management increased its position in Johnson & Johnson by 54.1% during the 4th quarter. Monument Capital Management now owns 2,123 shares of the company’s stock valued at $307,000 after purchasing an additional 745 shares during the period. Finally, MOKAN Wealth Management Inc. acquired a new stake in Johnson & Johnson during the 4th quarter valued at approximately $1,739,000. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Raymond James decreased their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Leerink Partners decreased their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Bank of America reduced their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, January 23rd. Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Finally, Wolfe Research initiated coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective for the company. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $170.67.

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $157.93 on Thursday. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock’s fifty day simple moving average is $148.34 and its two-hundred day simple moving average is $155.86. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The stock has a market cap of $380.23 billion, a PE ratio of 23.75, a price-to-earnings-growth ratio of 2.50 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same period last year, the business earned $2.29 EPS. The business’s revenue was up 5.3% on a year-over-year basis. As a group, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.14%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.